INTRODUCTION: Advanced thymoma (stage III and IV) is difficult to detect by computed tomography (CT), yet it is important to distinguish between early (stage I and II) and advanced disease before surgery, as patients with locally advanced tumors require neoadjuvant chemotherapy to enable effective resection. This study assessed whether the amount of fluorodeoxyglucose (FDG) uptake can predict advanced thymoma and whether it can separate thymoma from thymic cancer. METHODS: We retrospectively reviewed FDG positron emission tomography (PET)-CT scans of 51 consecutive newly diagnosed patients with thymic epithelial malignancy. PET-CT findings documented focal FDG activity: SUVmax, SUVmean, SUVpeak, and total body volumetric standardized uptake value (SUV) measurements. These were correlated with Masaoka-Koga staging and World Health Organization classification. Wilcoxon ranked sum tests were used to assess association between SUV and pathological stage, cancer type, and classification. RESULTS: Among the study patients, 37 had thymoma, 12 thymic carcinoma, and 2 thymic carcinoid. Higher focal FDG uptake was seen in patients with type B3 thymoma than in those with type A, AB, B1, or B2 thymoma (p < 0.006). FDG uptake was higher in patients with thymic carcinoma or carcinoid than in patients with thymoma (p < 0.0003), with more variable associations with volumetric SUV measurements. There was no significant association observed between higher focal FDG uptake and advanced-stage disease in thymoma patients (p > 0.09), although greater FDG-avid tumor volume was significantly associated with advanced disease (p < 0.03). CONCLUSIONS: Focal FDG uptake cannot predict advanced thymoma but is helpful in distinguishing thymoma from thymic carcinoma, or the more aggressive thymoma, type B3.
INTRODUCTION:Advanced thymoma (stage III and IV) is difficult to detect by computed tomography (CT), yet it is important to distinguish between early (stage I and II) and advanced disease before surgery, as patients with locally advanced tumors require neoadjuvant chemotherapy to enable effective resection. This study assessed whether the amount of fluorodeoxyglucose (FDG) uptake can predict advanced thymoma and whether it can separate thymoma from thymic cancer. METHODS: We retrospectively reviewed FDG positron emission tomography (PET)-CT scans of 51 consecutive newly diagnosed patients with thymic epithelial malignancy. PET-CT findings documented focal FDG activity: SUVmax, SUVmean, SUVpeak, and total body volumetric standardized uptake value (SUV) measurements. These were correlated with Masaoka-Koga staging and World Health Organization classification. Wilcoxon ranked sum tests were used to assess association between SUV and pathological stage, cancer type, and classification. RESULTS: Among the study patients, 37 had thymoma, 12 thymic carcinoma, and 2 thymic carcinoid. Higher focal FDG uptake was seen in patients with type B3 thymoma than in those with type A, AB, B1, or B2 thymoma (p < 0.006). FDG uptake was higher in patients with thymic carcinoma or carcinoid than in patients with thymoma (p < 0.0003), with more variable associations with volumetric SUV measurements. There was no significant association observed between higher focal FDG uptake and advanced-stage disease in thymomapatients (p > 0.09), although greater FDG-avid tumor volume was significantly associated with advanced disease (p < 0.03). CONCLUSIONS: Focal FDG uptake cannot predict advanced thymoma but is helpful in distinguishing thymoma from thymic carcinoma, or the more aggressive thymoma, type B3.
Authors: Ralf J Rieker; Josef Hoegel; Alicia Morresi-Hauf; Walter J Hofmann; Hendrik Blaeker; Roland Penzel; Herwart F Otto Journal: Int J Cancer Date: 2002-04-20 Impact factor: 7.396
Authors: Gerald Antoch; Jörg Stattaus; Andre T Nemat; Simone Marnitz; Thomas Beyer; Hilmar Kuehl; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg Journal: Radiology Date: 2003-09-25 Impact factor: 11.105
Authors: Muhammad Al-Hajj; Michael W Becker; Max Wicha; Irving Weissman; Michael F Clarke Journal: Curr Opin Genet Dev Date: 2004-02 Impact factor: 5.578
Authors: D Blumberg; J L Port; B Weksler; R Delgado; J Rosai; M S Bains; R J Ginsberg; N Martini; P M McCormack; V Rusch Journal: Ann Thorac Surg Date: 1995-10 Impact factor: 4.330
Authors: Lorenzo Falchi; Michael J Keating; Edith M Marom; Mylene T Truong; Ellen J Schlette; Rachel L Sargent; Long Trinh; Xuemei Wang; Susan C Smith; Nitin Jain; Zeev Estrov; Susan O'Brien; William G Wierda; Susan Lerner; Alessandra Ferrajoli Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: Robert J Korst; Sumudinie Fernando; Ann Christine Catlin; John R Rutledge; Nicolas Girard; James Huang; Frank Detterbeck Journal: Ann Thorac Surg Date: 2017-10-21 Impact factor: 4.330
Authors: Vincent Thomas de Montpreville; Audrey Mansuet-Lupo; Cécile Le Naoures; Lara Chalabreysse; Anne De Muret; Véronique Hofman; Isabelle Rouquette; Nicolas Piton; Romain Dubois; Jose Carlos Benitez; Nicolas Girard; Benjamin Besse; Alexander Marx; Thierry Jo Molina Journal: Virchows Arch Date: 2021-02-24 Impact factor: 4.064